PTP1B Is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer - Abstract

The androgen receptor (AR) signaling axis plays a key role in the pathogenesis of prostate cancer.

In this study, we found that the protein tyrosine phosphatase PTP1B, a well-established regulator of metabolic signaling, was induced after androgen stimulation of AR-expressing prostate cancer cells. PTP1B induction by androgen occurred at the mRNA and protein levels to increase PTP1B activity. High-resolution chromosome mapping revealed AR recruitment to two response elements within the first intron of the PTP1B encoding gene PTPN1, correlating with an AR-mediated increase in RNA polymerase II recruitment to the PTPN1 transcriptional start site. We found that PTPN1 and AR genes were coamplified in metastatic tumors and that PTPN1 amplification was associated with a subset of high-risk primary tumors. Functionally, PTP1B depletion delayed the growth of androgen-dependent human prostate tumors and impaired androgen-induced cell migration and invasion in vitro. However, PTP1B was also required for optimal cell migration of androgen-independent cells. Collectively, our results established the AR as a transcriptional regulator of PTPN1 transcription and implicated PTP1B in a tumor-promoting role in prostate cancer. Our findings support the preclinical testing of PTP1B inhibitors for prostate cancer treatment.

Written by:
Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, Tremblay ML Are you the author?
Goodman Cancer Research Centre, Department of Medicine, Division of Experimental Medicine; Department of Biochemistry and Oncology, McGill University; Service d'anatomopathologie, Hôpital du Sacré-Cœur de Montréal; Centre de recherche du CHUM (CR-CHUM), and Institut du cancer de Montréal; Department of Medicine, Université de Montréal; Department of Surgery, CHUM, Université de Montréal, Montréal, Québec, Canada; and Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

Reference: Cancer Res. 2012 Mar 15;72(6):1529-1537
doi: 10.1158/0008-5472.CAN-11-2602

PubMed Abstract
PMID: 22282656